HU224496B1 - Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HU224496B1
HU224496B1 HU9503153A HU9503153A HU224496B1 HU 224496 B1 HU224496 B1 HU 224496B1 HU 9503153 A HU9503153 A HU 9503153A HU 9503153 A HU9503153 A HU 9503153A HU 224496 B1 HU224496 B1 HU 224496B1
Authority
HU
Hungary
Prior art keywords
piperidines
alkyl
pharmaceutical compositions
compositions containing
substituted pyrrolidin
Prior art date
Application number
HU9503153A
Other languages
English (en)
Other versions
HUT74085A (en
HU9503153D0 (en
Inventor
Timothy P. Burkholder
Elizabeth M. Kudlacz
Tieu-Binh Le
George D. Maynard
Original Assignee
Merrel Dow Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrel Dow Pharmaceuticals Inc. filed Critical Merrel Dow Pharmaceuticals Inc.
Publication of HU9503153D0 publication Critical patent/HU9503153D0/hu
Publication of HUT74085A publication Critical patent/HUT74085A/hu
Publication of HU224496B1 publication Critical patent/HU224496B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU9503153A 1993-05-06 1994-04-22 Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények HU224496B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5860693A 1993-05-06 1993-05-06
US21848394A 1994-03-28 1994-03-28
US22537194A 1994-04-19 1994-04-19

Publications (3)

Publication Number Publication Date
HU9503153D0 HU9503153D0 (en) 1996-01-29
HUT74085A HUT74085A (en) 1996-11-28
HU224496B1 true HU224496B1 (hu) 2005-10-28

Family

ID=27369482

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9503153A HU224496B1 (hu) 1993-05-06 1994-04-22 Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények

Country Status (18)

Country Link
EP (1) EP0696280B1 (hu)
JP (1) JP3424174B2 (hu)
CN (1) CN1081635C (hu)
AT (1) ATE158580T1 (hu)
AU (1) AU678023B2 (hu)
CA (1) CA2160462C (hu)
DE (1) DE69405862T2 (hu)
DK (1) DK0696280T3 (hu)
ES (1) ES2110761T3 (hu)
FI (1) FI113047B (hu)
GR (1) GR3025475T3 (hu)
HU (1) HU224496B1 (hu)
IL (1) IL109496A (hu)
MX (1) MX9403386A (hu)
NO (1) NO309144B1 (hu)
NZ (1) NZ267209A (hu)
TW (1) TW281675B (hu)
WO (1) WO1994026735A1 (hu)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
NZ292683A (en) 1994-08-25 1998-07-28 Merrell Pharma Inc Piperidine derivatives
CA2162786A1 (en) * 1994-11-22 1996-05-23 Philip Arthur Hipskind Heterocyclic tachykinin receptor antagonists
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2215333C (en) * 1995-03-15 2002-01-01 Hoechst Marion Roussel, Inc. Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
KR100414321B1 (ko) * 1995-04-13 2004-02-18 아벤티스 파마슈티칼스 인크. 타치키닌수용체길항활성을갖는신규한치환된피페라진유도체
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
CA2228572C (en) * 1995-10-10 2003-07-22 Giovanni Piedimonte Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
KR20000064487A (ko) * 1995-12-20 2000-11-06 게리 디. 스트리트, 스티븐 엘. 네스비트 알레르기질환의치료에유용한신규의치환된4-(1h-벤즈이미다졸-2-일)1,4디아제판
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5977139A (en) * 1996-12-15 1999-11-02 Hoechst Marion Roussel, Inc. Carboxysubstituted cyclic carboxamide derivatives
DE69710921T2 (de) * 1996-12-19 2002-09-19 Aventis Pharmaceuticals Inc., Bridgewater Heterocyclische substituierte pyrrolidinamid-derivate
CN1098259C (zh) * 1996-12-19 2003-01-08 阿温蒂斯药物公司 新的羧基取代的环状羧酰胺衍生物
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
KR100432210B1 (ko) 1997-05-30 2004-05-20 상꾜 가부시키가이샤 광학활성 술폭사이드 유도체의 염
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
JP2006511552A (ja) * 2002-12-13 2006-04-06 スミスクライン ビーチャム コーポレーション Ｃｃｒ５拮抗薬としてのピロリジンおよびアゼチジン化合物
TW200524868A (en) 2003-07-31 2005-08-01 Zeria Pharm Co Ltd Benzylamine derivatives
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1804919B1 (en) * 2004-10-22 2011-03-30 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2601709C (en) 2005-03-22 2017-02-14 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
WO2007011878A2 (en) 2005-07-19 2007-01-25 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
RU2008116844A (ru) 2005-09-29 2009-11-10 Мерк энд Ко., Инк. (US) Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
MX2009007916A (es) 2007-01-24 2009-07-31 Glaxo Group Ltd Composiciones farmaceuticas que comprenden 3,5-diamino-6-(2,3-dicl orofenil)-l,2,4,-triazina; o r(-)-2,4-diamino-5-(2,3-diclorofenil) -6-fluorometil pirimidina y un receptor neuroquinina 1.
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011137012A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103269584B (zh) 2010-07-01 2017-05-03 阿泽凡药物公司 用于治疗创伤后应激障碍的方法
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
CN105073746B (zh) 2012-12-20 2017-03-22 默沙东公司 作为hdm2抑制剂的取代的咪唑并吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
RU2742773C2 (ru) 2014-03-28 2021-02-10 Азеван Фармасьютикалз, Инк. Композиции и способы лечения нейродегенеративных заболеваний
EP3317279B1 (en) * 2015-07-03 2021-01-27 H. Hoffnabb-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
US11628160B2 (en) 2017-09-15 2023-04-18 Azevan Pharmaceuticals, Inc. Compositions and methods for treating brain injury
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU678023B2 (en) 1997-05-15
HUT74085A (en) 1996-11-28
NO954400D0 (no) 1995-11-03
JP3424174B2 (ja) 2003-07-07
CN1081635C (zh) 2002-03-27
NO309144B1 (no) 2000-12-18
FI113047B (fi) 2004-02-27
JPH09500361A (ja) 1997-01-14
DE69405862T2 (de) 1998-01-15
HU9503153D0 (en) 1996-01-29
DK0696280T3 (da) 1998-01-12
DE69405862D1 (de) 1997-10-30
EP0696280B1 (en) 1997-09-24
CA2160462A1 (en) 1994-11-24
WO1994026735A1 (en) 1994-11-24
IL109496A (en) 2000-07-26
EP0696280A1 (en) 1996-02-14
FI955258A0 (fi) 1995-11-02
CN1124961A (zh) 1996-06-19
NZ267209A (en) 1997-09-22
AU6942694A (en) 1994-12-12
TW281675B (hu) 1996-07-21
NO954400L (no) 1996-01-08
ATE158580T1 (de) 1997-10-15
CA2160462C (en) 1998-12-15
FI955258A (fi) 1995-11-30
GR3025475T3 (en) 1998-02-27
ES2110761T3 (es) 1998-02-16
IL109496A0 (en) 1994-08-26
MX9403386A (es) 1995-01-31

Similar Documents

Publication Publication Date Title
IL109496A0 (en) Substituted pyrrolidin-3-yl-alkyl-piperidines and pharmaceutical compositions containing them
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
MD1233C2 (ro) Derivaţi de eritromicină, procedeu de preparare a lor şi compoziţie farmaceutică pe baza acestora
DE69725608D1 (de) Indolin-2-one derivate, verfahren zu ihrer herstellung und dieseenthaltende arzneimittel
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
CA2277949A1 (en) Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
CA2234610A1 (en) New amino acid derivatives, processes for preparing them and pharmaceutical compositions containing these compounds
TNSN97014A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
CA2137748A1 (en) Amidinophenylalanine derivatives, a process for their preparation, their use and compositions containing these as anticoagulants
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
GEP20002271B (en) Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use
CA2087922A1 (en) 8-(1-aminocycloalkyl)-1,3-dialkylxanthine derivatives, preparation process and antidepressant, nootropic and psychostimulant composition thereof
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
IL134194A0 (en) Streptogramines, their preparation and compositions containing them
ES8304923A1 (es) Un procedimiento para la preparacion de un peptido.
GEP20002241B (en) Polymorphs and Hydrated Forms of Lesopitron Dichlorohydrate, Methods for Its Preparation and Pharmaceutical Compositions Containing Same
AU5662996A (en) Compounds and compositions for delivering active agents
RU94010096A (ru) Производное 1,2,5,6-тетрагидропиридина, способ его получения и фармацевтическая композиция
CA2215372A1 (en) Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
ITMI922969A0 (it) Nuovi peptidi sintetici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro impiego per la somministrazione di farmaci attraverso la barriera emato-encefalica e la retina.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050815

HMM4 Cancellation of final prot. due to non-payment of fee
MM4A Lapse of definitive patent protection due to non-payment of fees